Is your child suffering from seizures and less than 2 years of age? If so, your child may qualify for the Jazz Piccolo Study! The Jazz Piccolo Study (Piccolo means “little one” in Italian) is investigating the safety and effectiveness of cannabidiol (or CBD oral solution) in infants (2 years of age and younger) with Tuberous Sclerosis Complex (TSC), Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS) who experience inadequately controlled seizures.
TSC, LGS and DS are rare, early-onset epilepsies with life-long impact. Current treatment options for seizures associated with these conditions have substantial limitations, including poor seizure control and numerous side effects. Studies have shown that poor seizure control leads to additional health issues and a lower quality of life for those affected. Therefore, early treatment and control of seizures may be critical in improving the outcomes for children with these conditions. To find out if your chil
What is Lennox-Gastaut Syndrome? Lennox-Gastaut Syndrome (LGS) is a severe epilepsy syndrome that develops in young children and often leads to lifelong disability. Nobody is born with LGS. It develops over time. LGS is a rare disease (approximately one person in every 2,000). About 50,000 people in the United States and 1 million people worldwide have LGS. For more information on LGS, please visit www.lgsfoundation.org .